Article in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors.
Huihui HuangDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8853-8379
Yi WangDepartment of Cardiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0291-5314
Zsuzsanna K ZsengellerDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4540-5728
Joshua M GorhamDepartment of Genetics, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5969-4690
Vamsidhara VemireddyDivision of Nephrology, Department of Internal Medicine, and Department of Pharmacology, University of Texas Southwestern, Dallas, TX, USA.ORCID 0000-0001-7068-6640
Amanda J ClarkDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6550-730X
Hui PanBioinformatics and Biostatistics Core, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5748-7217
Jonathan M DreyfussBioinformatics and Biostatistics Core, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7242-3991
Vasantha JotwaniKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-1913-3957
Michael G ShlipakKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco, San Francisco, CA, USA.
Mark J SarnakDivision of Nephrology, Tufts Medical Center, Boston, MA, USA.
Chirag R ParikhDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-9051-7385
Heather Thiessen-PhilbrookDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2067-0514
Ronit KatzDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.ORCID 0000-0001-7723-7469
Sushrut S WaikarSection of Nephrology, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA, USA.ORCID 0000-0003-4004-326X
Nicole J LakeDepartment of Genetics, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-4103-6387
Monkol LekDepartment of Genetics, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-1227-6293
Wen ShiMcKusick-Nathans Institute, Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2886-2361
Daniela PuiuMcKusick-Nathans Institute, Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2386-9265
Yun Soo HongMcKusick-Nathans Institute, Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2438-5641
Jonathan G SeidmanDepartment of Genetics, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9082-3566
Dan E ArkingMcKusick-Nathans Institute, Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-8980-8695
Samir M ParikhDivision of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1038-981X
Funding
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeff G McDonald · 2022 to 2026
$7.4M
The Aging Kidney: Chronic Injury, Impaired Functions and Clinical OutcomesR01AG027002 · NIA · TUFTS MEDICAL CENTER · PI PARIKH, SAMIR M, SARNAK, MARK J · 2005 to 2022
$7.3M
Tie2-driven vascular control in critical illnessR35HL139424 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI PARIKH, SAMIR M · 2018 to 2024
$6.4M
Mitochondrial Biogenesis in Kidney DiseaseR01DK095072 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Samir M Parikh · 2012 to 2026
$5.3M
Mitochondrial DNA heteroplasmy and risk for atherosclerotic cardiovascular disease (ASCVD)R01HL144569 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI ARKING, DAN E · 2019 to 2022
$3.1M
Mitochondrial Function and Multiomics in Aging-related Disease: Identifying Novel Biomarkers and Causal RelationshipsR01AG085753 · NIA · JOHNS HOPKINS UNIVERSITY · PI Dan E Arking · 2024 to 2026
$2.0M
Novel Human Biomarkers of Kidney FibrosisU01DK104308 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HUMPHREYS, BENJAMIN D., WAIKAR, SUSHRUT S. · 2014 to 2018
$2.0M
Restoration of reduced nitric oxide bioavailability in PreeclampsiaR21HD115117 · NICHD · BETH ISRAEL DEACONESS MEDICAL CENTER · PI POLLAK, MARTIN R. · 2024 to 2025
$469k
Radiocontrast Nephropathy: Redox Degradation Catalyst and Nitric Oxide DonorR43DK097843 · NIDDK · RADIKAL THERAPEUTICS, INC. · PI ZSENGELLER, ZSUZSANNA KINGA · 2013 to 2013
$245k
Organophosphate intoxication: effect of PARS inhibitionR43ES011921 · NIEHS · INOTEK PHARMACEUTICALS CORPORATION · PI ZSENGELLER, ZSUZSANNA KINGA · 2004 to 2004
$240k
Novel xanthine oxidase inhibitor for arthritisR43AR048731 · NIAMS · INOTEK PHARMACEUTICALS CORPORATION · PI ZSENGELLER, ZSUZSANNA KINGA · 2004 to 2004
Somatically acquired mitochondrial DNA (mtDNA) mutations accumulate with age, but the mechanisms and consequences of this accumulation are poorly understood. Here we show that transient injuries induce a burst of persistent mtDNA mutations that impair resilience to future injuries. mtDNA mutations suppressed energy-intensive nucleotide metabolism. Repletion of adenosine, but not other nucleotides, restored adenosine triphosphate generation, which required a nuclear-encoded purine biosynthetic enzyme, adenylate kinase 4 (AK4). Analysis of 369,912 UK Biobank participants revealed a graded association between mutation burden and chronic kidney disease severity as well as an independent increase in the risk of future acute kidney injury events (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Reversible compromise of physiological resilience by accumulation of heteroplasmic mtDNA mutations. · full record | OpenQuestion